ERBB2 and breast cancer: In 2007, success of the Phase III clinical trial, NCT00078572, led to the FDA approval of lapatinib in combination with capecitabine for treatment-naïve, ER+/EGFR+/HER2+ breast cancers (Table 1) [62].